Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy

Lizza E. Hendriks*, Etienne Rouleau, Benjamin Besse

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)647-660
Number of pages14
JournalTranslational Lung Cancer Research
Volume7
Issue number6
DOIs
Publication statusPublished - Dec 2018

Keywords

  • Immunotherapy
  • mutation/immunology
  • non-small cell lung cancer (NSCLC)
  • predictive value of tests
  • programmed death-ligand 1 (PD-L1)
  • RANDOMIZED CONTROLLED-TRIAL
  • DNA MISMATCH REPAIR
  • PD-1 BLOCKADE
  • CHECKPOINT BLOCKADE
  • OPEN-LABEL
  • DOCETAXEL
  • ATEZOLIZUMAB
  • NEOANTIGENS
  • MULTICENTER
  • LANDSCAPE

Cite this